List of SBIR/STTR awards granted to Abzyme Therapeutics
Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Abzyme Therapeutics in September, 2021 for $399,107.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43NS120624-01A1 | Phase I | 399,107 | September 15, 2021 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in September, 2019 for $299,989.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43EY030821-01 | Phase I | 299,989 | September 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in August, 2019 for $280,352.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI151635-01A1 | Phase I | 280,352 | August 14, 2019 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics for $299,999.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 75N91018C00031-0-0-0 | Phase I | 299,999 | ||||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics for $299,815.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 75N93019C00009 | Phase I | 299,815 | ||||||||
A SBIR Phase II contract was awarded to Abzyme Therapeutics in November, 2017 for $499,999.05 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. | SBIR | W911QY-18-C-0004 | Phase II | 499,999.05 | November 15, 2017 | |||||||
A SBIR Phase II contract was awarded to Abzyme Therapeutics in September, 2016 for $1,670,345.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44GM106519-02 | Phase II | 1,670,345 | September 1, 2016 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in September, 2017 for $224,926.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43GM122126-01A1 | Phase I | 224,926 | September 15, 2017 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in December, 2015 for $149,964.61 USD from the U.S. Department of Defense. | SBIR | W911QY-16-P-0050 | Phase I | 149,964.61 | December 22, 2015 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in June, 2015 for $264,747.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA193101-01 | Phase I | 264,747 | June 1, 2015 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in February, 2015 for $224,935.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43EY025123-01 | Phase I | 224,935 | February 3, 2015 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in September, 2017 for $236,646.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43NS105172-01 | Phase I | 236,646 | September 25, 2017 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in July, 2015 for $224,799.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43GM115011-01 | Phase I | 224,799 | July 1, 2015 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in June, 2016 for $149,656.59 USD from the U.S. Department of Defense. | SBIR | W911QY-16-P-0229 | Phase I | 149,656.59 | June 14, 2016 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in July, 2016 for $224,638.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DA042461-01 | Phase I | 224,638 | July 1, 2016 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics for $224,849.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI114214-01 | Phase I | 224,849 | ||||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics for $224,975.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DA038980-01 | Phase I | 224,975 | ||||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics for $282,519.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AG039892-01 | Phase I | 282,519 | ||||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics for $218,085.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43GM106519-01A1 | Phase I | 218,085 | ||||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in April, 2015 for $99,943.0 USD from the U.S. Department of Agriculture. | SBIR | 2015-33610-23498 | Phase I | 99,943 | April 23, 2015 | |||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics for $99,973.0 USD from the U.S. Department of Agriculture. | SBIR | 2014-00575 | Phase I | 99,973 | ||||||||
A SBIR Phase I contract was awarded to Abzyme Therapeutics in May, 2023 for $299,999.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI174703-01A1 | Phase I | 299,999 | May 22, 2023 |
